[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349951-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349951-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-chemotherapy-and-immunotherapy-roles-of-gpr37gpr37l1-in-pan-cancer","Prognostic, chemotherapy and immunotherapy roles of GPR37/GPR37L1 in pan-cancer","","G protein-coupled receptor 37 (GPR37) and G protein-coupled receptor 37 like 1 (GPR37L1) are implicated in tumorigenesis, yet their prognostic relevance and effects on chemotherapy and immunotherapy responses across cancers remain incompletely characterized. Using transcriptomic, genomic, pharmacogenomic, and clinical datasets, the study mapped molecular landscapes and linked receptor alterations and expression to survival and treatment sensitivity. Results identify GPR37 and GPR37L1 as candidate biomarkers for prognostic stratification and response prediction, supported by immune infiltration and chemokine patterns.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-chemotherapy-and-immunotherapy-roles-of-gpr37gpr37l1-in-pan-cancer/349951/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-chemotherapy-and-immunotherapy-roles-of-gpr37gpr37l1-in-pan-cancer/349951.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on GPR37 and GPR37L1?","Question",{"text":63,"@type":64},"To determine how GPR37 and GPR37L1 relate to prognosis and how they may influence chemotherapy and immunotherapy responses across diverse cancers using multi-omics and clinical datasets.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess chemotherapy response?",{"text":68,"@type":64},"By correlating GPR37 and GPR37L1 expression levels with sensitivity to 21 common chemotherapeutic agents, including examples where higher receptor expression reduced sensitivity to cisplatin and gemcitabine in lung adenocarcinoma.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the immunotherapy analysis show for melanoma?",{"text":72,"@type":64},"In melanoma cohorts treated with immunotherapy, higher GPR37 or GPR37L1 expression was associated with inferior overall survival, supported by immune infiltration and chemokine profiling.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349951,1791413505,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","®  \n Observational Study   \nPrognostic, chemotherapy and immunotherapy roles of GPR37/GPR37L1 in pan-cancer  \nGuoqiang Zhu, MSa , Jiliang He, BSa , Ningkun Shi, BSa , Zhongyao Cai, BSb , Jiannan Zhang, PhDa , Susanna Chau Yi Wang, BSc , Juan Li, PhDa , Mao Zhang, MDd , Yajun Wang, PhDa ,*  \n\n| Abstract\u003Cbr>G protein-coupled receptor 37 (GPR37) and G protein-coupled receptor 37 like 1 (GPR37L1) are implicated in tumorigenesis; however, their prognostic significance and roles in chemotherapy and immunotherapy responses across diverse cancers is incompletely defined. Utilizing transcriptomic, genomic, pharmacogenomic, and clinical data, we mapped the molecular landscapes of GPR37 and GPR37L1 and assessed their potential clinical value in retrospective real-world cohorts. Our analysis revealed high genetic alteration rates for GPR37 (10 .2%) and GPR37L1 (10 .7%) . Aberrant expression of GPR37 served as a predictive biomarker for survival outcomes in breast invasive carcinoma, lower grade gliomas, and lung adenocarcinoma, a pattern similarly observed for GPR37L1 . Intriguingly, the 2 receptors exhibited divergent prognostic effects in adrenocortical carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, uterine corpus endometrial carcinoma, and uveal melanoma. Evaluation of chemotherapy response identified significant correlations between the expression levels of both GPR37 and GPR37L1 and sensitivity to 21 common chemotherapeutic agents. For example, in lung adenocarcinoma, the elevated expression of either receptor was significantly associated with reduced sensitivity tocisplatin and gemcitabine. Analysis of 2 immunotherapy-treated melanoma cohorts demonstrated that high GPR37 or GPR37L1 expression correlated with inferior overall survival, a finding corroborated by immune infiltration and chemokine profiles. Our in vitro experiments demonstrated that the proposed ligand TX14A was unable to activate GPR37 and GPR37L1 through the cyclic adenosine monophosphate or extracellular signal-regulated kinase/mitogen-activated protein kinase pathways. Notably, this is the first systematic pan-cancer profiling of both GPR37 and GPR37L1 that integrates analyses of chemotherapy sensitivity, immunotherapy response, and immune landscapes. GPR37 and GPR37L1 may represent candidate biomarkers for prognostic stratification and for predicting chemotherapy and immunotherapy response. |\n| --- |\n| Abbreviations: ACC = adrenocortical carcinoma, BLCA = bladder urothelial carcinoma, BRCA = breast invasive carcinoma, cAMP = cyclic adenosine monophosphate, CESC = cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL = cholangiocarcinoma, COAD = colon adenocarcinoma, CR = complete response, ERK = extracellular signal-regulated kinase, ESCA = esophageal carcinoma, GBM = glioblastoma multiforme, GEO = gene expression omnibus, GPR37 = G protein-coupled receptor 37, GPR37L1 = G protein-coupled receptor 37 like 1, HNSC = head and neck squamous cell carcinoma, HR = hazard ratio, IC50 = half-maximal inhibitory concentration, KICH = kidney chromophobe, KIRC = kidney renal clear cell carcinoma, KIRP = kidney renal papillary cell carcinoma, KM = Kaplan–Meier, LGG = brain lower grade glioma, LIHC = liver hepatocellular carcinoma, LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, MESO = mesothelioma, mOS = median overall survival, PAAD = pancreatic adenocarcinoma, PCPG = pheochromocytoma and paraganglioma, PD = progressive disease, PR = partial response, PSAP = prosaposin, READ = rectum adenocarcinoma, SARC = sarcoma, SD = stable disease, SKCM = skin cutaneous melanoma, SRE = serum response element, STAD = stomach adenocarcinoma, TCGA = the cancer genome atlas, TGCT = testicular germ cell tumor, THCA = thyroid carcinoma, THYM = thymoma, UCEC = uterine corpus endometrial carcinoma, UCS = uterine carcinosarcoma, UVM = uveal melanoma. |\n| Keywords: GPR37, GPR37L1 , i","cbCaiaXQTLJmayIN","https://ap.wps.com/l/cbCaiaXQTLJmayIN","pdf",3929399,14,"English","# Abstract\n# Abbreviations\n# Keywords\n# Introduction","[{\"question\":\"What is the main goal of the study on GPR37 and GPR37L1?\",\"answer\":\"To determine how GPR37 and GPR37L1 relate to prognosis and how they may influence chemotherapy and immunotherapy responses across diverse cancers using multi-omics and clinical datasets.\"},{\"question\":\"How did the study assess chemotherapy response?\",\"answer\":\"By correlating GPR37 and GPR37L1 expression levels with sensitivity to 21 common chemotherapeutic agents, including examples where higher receptor expression reduced sensitivity to cisplatin and gemcitabine in lung adenocarcinoma.\"},{\"question\":\"What did the immunotherapy analysis show for melanoma?\",\"answer\":\"In melanoma cohorts treated with immunotherapy, higher GPR37 or GPR37L1 expression was associated with inferior overall survival, supported by immune infiltration and chemokine profiling.\"}]","Prognostic, chemotherapy and immunotherapy roles of GPR37/GPR37L1 in pan-cancer | PDF",1790086427,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cd9d826f8ce074e1d23ec8757bb0f0d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc92076ab8f6ec310745944171af0cf1.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca7b10e73e22d635b9db96b001ba76b6.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ca43da36bafe10dfa8400e9ef7116cb.webp",980,1306]